Literature DB >> 28958334

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

Carlo Patrono1, Joao Morais2, Colin Baigent3, Jean-Philippe Collet4, Desmond Fitzgerald5, Sigrun Halvorsen6, Bianca Rocca7, Agneta Siegbahn8, Robert F Storey9, Gemma Vilahur10.   

Abstract

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aspirin; cangrelor; clopidogrel; prasugrel; ticagrelor; vorapaxar

Mesh:

Substances:

Year:  2017        PMID: 28958334     DOI: 10.1016/j.jacc.2017.08.037

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  33 in total

1.  Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry.

Authors:  Catarina Ruivo; Fernando Montenegro Sá; Luís Graça Santos; Joana Correia; Adriana Belo; João Morais
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

Review 2.  Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.

Authors:  B E Stähli; U Landmesser
Journal:  Herz       Date:  2018-02       Impact factor: 1.443

3.  Should not we be using aspirin in patients with a ventriculoatrial shunt? Borrowing a leaf from other specialities: a case for surrogate evidence.

Authors:  Suhas Udayakumaran; Shine Kumar
Journal:  Childs Nerv Syst       Date:  2020-10-08       Impact factor: 1.475

Review 4.  Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.

Authors:  Nigel Mackman; Henri M H Spronk; George A Stouffer; Hugo Ten Cate
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-15       Impact factor: 8.311

5.  Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis.

Authors:  Thomas A Mavrakanas; Yiannis S Chatzizisis; Karim Gariani; Dean J Kereiakes; Giuseppe Gargiulo; Gérard Helft; Martine Gilard; Fausto Feres; Ricardo A Costa; Marie-Claude Morice; Jean-Louis Georges; Marco Valgimigli; Deepak L Bhatt; Laura Mauri; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-22       Impact factor: 8.237

6.  Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.

Authors:  Margaret Infeld; Kevin A Friede; Tan Ru San; Holly J Knickerbocker; Geoffrey S Ginsburg; Thomas L Ortel; Deepak Voora
Journal:  J Thromb Thrombolysis       Date:  2020-11-06       Impact factor: 2.300

7.  Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.

Authors:  Alberto Tosetto; Bianca Rocca; Giovanna Petrucci; Silvia Betti; Denise Soldati; Elena Rossi; Andrea Timillero; Viviana Cavalca; Benedetta Porro; Alessandra Iurlo; Daniele Cattaneo; Cristina Bucelli; Alfredo Dragani; Mauro Di Ianni; Paola Ranalli; Francesca Palandri; Nicola Vianelli; Eloise Beggiato; Giuseppe Lanzarone; Marco Ruggeri; Giuseppe Carli; Elena Maria Elli; Stefania Priolo; Maria Luigia Randi; Irene Bertozzi; Giuseppe Gaetano Loscocco; Alessandra Ricco; Giorgina Specchia; Alessandro Maria Vannucchi; Francesco Rodeghiero; Valerio De Stefano; Carlo Patrono
Journal:  Clin Pharmacol Ther       Date:  2021-11-20       Impact factor: 6.903

8.  Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome.

Authors:  Yuting Zou; Yuyan Wang; Yangxun Wu; Shizhao Zhang; Haiping Liu; Tong Yin
Journal:  Thromb J       Date:  2022-04-21

9.  Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia.

Authors:  Moua Yang; Wei Li; Calvin Harberg; Wenjing Chen; Hong Yue; Renan B Ferreira; Sarah L Wynia-Smith; Kate S Carroll; Jacek Zielonka; Robert Flaumenhaft; Roy L Silverstein; Brian C Smith
Journal:  Blood Adv       Date:  2020-09-22

10.  Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018.

Authors:  Mikkel B Christensen; Espen Jimenez-Solem; Martin T Ernst; Morten Schmidt; Anton Pottegård; Erik L Grove
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.